Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis

Arthritis Care and Research

Volumn 59, Issue 8, 2008, Pages 1074-1081

  Lacaille, Diane ^a,e   Guh, Daphne P ^b   Abrahamowicz, Michal ^c   Anis, Aslam H ^a   Esdaile, John M ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CANADA; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE DURATION; DRUG USE; FEMALE; FOLLOW UP; GOLD THERAPY; GROUPS BY AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POISSON DISTRIBUTION; POPULATION RESEARCH; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SOCIOECONOMICS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BRITISH COLUMBIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFECTION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POISSON DISTRIBUTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 49549124746     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23913     Document Type: Article

References (47)

1. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971;14:135-7.
2. Huskisson EC, Hart FD. Severe, unusual, and recurrent infections in rheumatoid arthritis. Ann Rheum Dis 1972;31:118-21.
3. Rowe IF, Deans AC, Keat AC. Pyogenic infection and rheumatoid arthritis. Postgrad Med J 1987;63:19-22.
4. Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis: a nested case-control study. J Rheumatol 1998;25:1900-7.
5. Rimoin DL, Wennberg JE. Acute septic arthritis complicating chronic rheumatoid arthritis. JAMA 1966;196:617-21.
6. Kellgren JH, Ball J, Fairbrother RW, Barnes KL. Suppurative arthritis complicating rheumatoid arthritis. Br Med J 1958;1:1193-200.
7. Goldenberg DL. Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders [review]. Arthritis Rheum 1989;32:496-502.
8. Mateo-Soria L, Sole JM, Sacanell AR, Garcia JV, Escofet DR. Infectious arthritis in patients with rheumatoid arthritis. Ann Rheum Dis 1992;51:402-3.
9. Kaandorp CJ, van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA. Risk factors for septic arthritis in patients with joint disease: a prospective study. Arthritis Rheum 1995;38.1819-25.
10. Kay A. Infection in rheumatoid arthritis. Lancet 1967;2:152.
11. Walker WC. Pulmonary infections and rheumatoid arthritis. Q J Med 1967;36:239-51.
12. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
13. Vandenbroucke JP, Kaaks R, Valkenburg HA, Boersma JW, Cats A, Festen JJ, et al. Frequency of infections among rheumatoid arthritis patients, before and after disease onset. Arthritis Rheum 1987;30:810-3.
14. Van Albada-Kuipers GA, Linthorst J, Peeters EA, Breedveld FC, Dijkmans BA, Hermans J, et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum 1988;31:667-71.
15. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Eng J Med 1953;249:553-6.
16. Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis Rheum 1970;13:125-30.
17. Abruzzo JL. Rheumatoid arthritis and mortality. Arthritis Rheum 1982;25:1020-3.
18. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol 1984;11:158-61.
19. Cosh JA. Survival and death in rheumatoid arthritis. J Rheumatol 1984;11:117-9.
20. Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-9.
21. Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985;290:1797-9.
22. Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990;49:363-9.
23. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995;13:149-53.
24. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005;53:241-8.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
26. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9.
27. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative databases. J Clin Epidemiol 1996;49:1429-33.
28. Zeger SL, Liang KY. Longitudinal data analysis and continuous outcomes. Biometrics 1986;42:121-30.
29. Waternaux C, Laird NM, Ware JH. Methods for analysis of longitudinal data: blood-lead concentrations and cognitive development. J Am Stat Assoc 1989;84:33-41.
30. Cox DR. Regression models and life tables. J Royal Stat Soc 1972;24:187-220.
31. Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991;21:1-11.
32. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse effects. Am J Med 1994;96:115-23.
33. Segal BH, Sneller MC. Life-threatening complications of autoimmune disease: infections complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 1997;23:220-37.
34. Singh G, Ramey DR, Rausch PL, Schettler JD. Serious infections in rheumatoid arthritis: relationship to immunosuppressive use [abstract]. Arthritis Rheum 1999;42 Suppl 9:S242.
35. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
36. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34.
37. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
38. Anderson PA, West SG, Nordstrom DM. Toxicity of chronic therapy with pulse methotrexate (MTX) in rheumatoid arthritis: potential increased risk of infection [abstract]. Arthritis Rheum 1987;30 Suppl 9:S60.
39. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
40. Van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994;53:224-8.
41. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-21.
42. Abrahamowicz M, Tamblyn R. Drug utilization patterns. In: Armitage P, Colton T, editors. Encyclopedia of biostatistics. Chichester (UK): John Wiley & Sons; 2005. p. 1533-53.
43. Abrahamowicz M, Xiao Y, Ionescu-Ittu R, Lacaille D. Simulations showed that validation of database-derived diagnostic criteria based on a small subsample reduced bias. J Clin Epidemiol 2007;60:600-9.
44. MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000;284:984-92.
45. MacLean CH, Park GS, Traina SB, Liu HH, Hahn BH, Paulus HE, et al. Positive predictive value (PPV) of an administrative data-based algorithm for the identification of patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001;44 Suppl 9:S106.
46. Silman A, Hochberg MC. Rheumatoid arthritis. In: Silman A, Hochberg MC, editors. Epidemiology of the rheumatic diseases. Oxford: Oxford University; 1993. p. 7-68.
47. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1998.